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Abstract
Background: Plasmodium falciparum merozoite surface protein-1 (MSP1) has been extensively studied as a blood-
stage malaria vaccine candidate, with most work focused on the conserved 19 kDa and semi-conserved 42 kDa C-
terminal regions (blocks 16-17) and the hypervariable N-terminal repeat region (block 2). However, recent
genotyping studies suggest that additional regions of MSP1 may be under selective pressure, including a locus of
intragenic recombination designated as block 4 within the 3’ region of the gene.
Methods: The current study examined the antibody response to the two parental and two recombinant forms of
block 4 and to blocks 16-17 (3D7) in study populations from Colombia, Papua New Guinea and Cameroon that
differ in malaria transmission intensity and ethnic composition.
Results: IgM and IgG antibodies were detected against parental and recombinant MSP1 block 4 peptides in all
three populations. Overall, 32-44% of the individuals produced IgM to one or more of the peptides, with most
individuals having IgM antibodies reactive with both parental and recombinant forms. In contrast, IgG seropositivity
to block 4 varied among populations (range 15-65%), with the majority of antibodies showing specificity for one or
a pair of block 4 peptides. The IgG response to block 4 was significantly lower than that to blocks 16-17, indicating
block 4 is subdominant. Antibodies to block 4 and blocks 16-17 displayed distinct IgG subclass biases, with block 4
responses biased toward IgG3 and blocks 16-17 toward IgG1. These patterns of responsiveness were consistently
observed in the three study populations.
Conclusions: Production of antibodies specific for each parental and recombinant MSP1 block 4 allele in different
populations exposed to P. falciparum is consistent with balancing selection of the MSP1 block 4 region by the
immune response of individuals in areas of both low and high malaria transmission. MSP1 block 4 determinants
may be important in isolate-specific immunity to P. falciparum.
Background
Plasmodium falciparum merozoite surface protein 1
(MSP1) is a candidate antigen for inclusion in a blood
stage malaria vaccine because it is thought to play a role
in erythrocyte invasion [1]. The MSP1 gene has been
divided into 17 sequence blocks that are conserved, semi-
conserved, or variable [2]. The semi-conserved and vari-
able regions are generally dimorphic, with the prototype
MSP1 alleles represented by the K1 and MAD20 parasite
isolates. Exceptions to this dimorphism are tripeptide
repeat sequences comprising block 2, which are of vari-
able length and composition, and a RO33 non-repetitive
block 2 variant. In addition, the MSP1 gene contains sev-
eral loci of intragenic recombination which represent
another potential source of antigenic polymorphism [2].
While it has been suggested that intragenic recombina-
tion can occur throughout the MSP1 gene, recombina-
tion sites in the 5’ region (conserved blocks 3 and 5, and
variable block 4) and in the 3’ region (block 17) have
been identified [3]. Sequence analysis of 34 full-length
MSP1 sequences has provided no evidence of recombina-
tion in blocks 6 through 16 [4].
In a previous study, the genetic composition of poly-
morphic MSP1 regions of P. falciparum obtained from
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malaria transmission was examined [5]. There was
restricted genetic diversity of MSP1 in this population,
with a high level of conservation within blocks 2, 6, and
16-17 that corresponded exclusively to the MAD20 alle-
lic type. In contrast, four MSP1 block 4 types corre-
sponding to the K1 and MAD20 parental and
recombinant sequences were detected. The persistence
of both parental and recombinant alleles of block 4
despite the restricted heterogeneity throughout the rest
of the gene suggested that block 4 allelic diversity may
be under balancing selection.
This study examined the recognition of MSP1 block 4
by antibodies of humans exposed to P. falciparum infec-
tion in order to begin to address the potential immuno-
logical significance of MSP1 block 4 sequence
variability. The study populations examined were from
three different countries with varying P. falciparum
transmission intensities. IgM and IgG antibodies to
block 4 peptides were measured to determine the sero-
prevalence and magnitude of the block 4 responses. The
specificity of antibodies produced against block 4 epi-
topes were characterized as cross-reactive or allele-spe-
cific, and thus capable of discriminating among parental
and recombinant block 4 sequences. Finally, the IgG iso-
type distribution of antibodies specific for block 4 as
compared to those specific for blocks 16-17 was com-
pared. A basic question addressed in these experiments
was: are antibodies specific for each parental and recom-
binant MSP1 block 4 allele found in different popula-
tions exposed to P. falciparum?I fs o ,t h i sw o u l db e
consistent with balancing selection of the MSP1 block 4
region by the immune response of individuals in areas
of both low and high malaria transmission.
Methods
Study populations
The patient samples examined were archived sera col-
lected from regions of varying endemicity for P. falci-
parum malaria. All samples were derived from research
protocols that had been approved by the appropriate
Human Use Review Committees in the originating
country as well as at the US collaborating institutions.
Informed consent was obtained from each study subject
prior to enrollment. Use of these samples for this study
was approved by the University of Hawaii Committee
on Human Studies.
Colombia (malaria uninfected and infected, asymptomatic)
The study site in Colombia was the village of Punta Sol-
dado in the Department of Valle del Cauca. Malaria
transmission in this area is considered to be low and
seasonal. Serum samples were collected in 1993 from a
study population consisting of 151 asymptomatic chil-
dren and adults within the following age groups: 1-4 y
(n = 10), 5-14 (n = 51), 15-29 (n = 44), and 30+ (n =
46)[6]. Fifty individuals (33.1%) were positive for P. falci-
parum by Giemsa-stained thick blood smears but were
asymptomatic. Sufficient serum for analysis in this study
was available for 111 of these samples.
Papua New Guinea (malaria uninfected and infected,
asymptomatic)
The study site was located in a rural area of intermedi-
ate malaria transmission 13 kilometers south of Madang,
Papua New Guinea. Sera were obtained in 1985-1986
from asymptomatic adult females at delivery (n = 101)
and from cord blood (n = 71)[7]. The prevalence of
malaria infection, predominantly P. falciparum,i nt h e
study population was 26% in mothers (mostly low den-
sity P. falciparum) prior to or immediately after delivery
and 4% in cord blood samples. Of these samples, 22
adult and 9 cord blood sera were available for this
study. Within this study population, 43.6% women
reported a history of malaria symptoms sometime dur-
ing their pregnancy [8].
Cameroon (malaria uninfected and infected, asymptomatic)
The study site was located in Ngali II, a rural Cameroo-
nian village. Plasma was obtained in 2001-2004 from 72
healthy adult volunteers (mean age 36.1 y, age range 14-
79 y), 37.5% of whom were blood smear positive for
Plasmodium falciparum. Plasmodium falciparum trans-
mission in this area is perennial and hyperendemic, with
an estimated exposure rate of ~300 infectious bites per
year. All 72 samples were tested for IgM antibodies,
while 64 of these samples were tested for IgG antibodies
due to limited availability of antigen-coated
microspheres.
Synthetic peptide and recombinant antigens
The malaria antigens used in the study included the
recombinant MSP-142 (3D7) polypeptide corresponding
to MSP1 blocks 16-17 expressed in Escherichia coli
(molecular weight, 42,000), produced by the Malaria
Vaccine Development Branch (MVDB), National Insti-
tute of Allergy and Infectious Disease, National Insti-
tutes of Health, Rockville, MD, and a set of synthetic
peptides corresponding to parental and recombinant
forms of MSP1 block 4. Synthetic peptides were synthe-
sized by Alpha Diagnostic International, Inc. (San Anto-
nio, TX). Peptides corresponding to the two parental
allelic forms of MSP1 block 4 were designated block 4-1
(K1 allele) and block 4-2 (MAD20 allele). Peptides cor-
responding to the two recombinant forms were desig-
nated block 4-3 (K1:MAD20) and block 4-4 (MAD20:
K1). The sequences of the peptides were:
Block 4-1 - NENIKELLDKINEIKNPPPANSGNTPNTL
LDKNKKIE (37-mer);
Block 4-2 - NENIKKLLEDIDKIKTDAENPTTGSKPNP
LPENKKKEVEG (40-mer);
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PENKKKEVEG (39-mer);
Block 4-4 - NENIKKLLEDIDKIKTDAEKPTTGSKPNT
LLDKNKKIE (38-mer)
Antigens were coupled to SeroMAP™ microspheres
according to a protocol previously described [9] using 5
μgo fM S P - 1 42 or 20 ug peptide coupled to five million
microspheres.
Multiplex assay for antibodies
A Luminex® bead-based multiplex serological assay was
used to measure antibodies to the four block 4 peptides
and to blocks 16-17 [9]. Briefly, antigen-coated micro-
spheres were mixed with diluted plasma (1:100 dilution)
in microtiter plates and incubated on a microplate shaker
(Lab-line, Melrose Park, IL) for 1 hour at 500 rpm. After
incubation, the plates were washed and microspheres
resuspended in buffer containing 1 mg/ml R-phycoery-
thrin-conjugated, F(ab’)2 fragment, goat anti-human IgG
(Fcg fragment specific) (Jackson ImmunoResearch, West
Grove, PA) or R-phycoerythrin-conjugated, F(ab’)2 frag-
ment, donkey anti-human IgM (Fc5μ fragment specific)
(Jackson ImmunoResearch, West Grove, PA). Plates were
incubated on a microplate shaker for 1 hour, washed and
resuspended. Resuspended microspheres were analysed
using a Liquichip M100 reader (QIAGEN, Valencia, CA).
For IgG subclass-specific assays, diluted plasma was incu-
bated with antigen-coated microspheres in microtiter
plates on a microplate shaker (Lab-line, Melrose Park, IL)
for 1 hour at 500 rpm. After incubation, the plates were
washed and microspheres resuspended in buffer contain-
ing the appropriate secondary antibody diluted to 1:1000
(mouse anti-human IgG1 Fc fragment specific (Calbio-
chem) or mouse anti-human IgG3 (Southern Biotechnol-
ogy)). Plates were incubated on a microplate shaker for 1
hour, washed and resuspended in 100 μlo f1μg/ml of R-
phycoerythrin-conjugated, F(ab’)2 fragment, donkey anti-
mouse IgG (H+L) (JacksonImmunoResearch, West
Grove, PA). In order to establish a cut-off for positive
samples, frequency distribution curves for median fluor-
escent intensity (MFI) values were plotted for each anti-
gen and the corresponding limits for negative and
positive samples were determined. This allowed for a bet-
ter assessment of the cut-off than the mean MFI plus
three standard deviations of the negative serum controls.
The following cut-off values were used in this study:
block 4 peptides IgM: 800 MFI; block 4 peptides IgG: 600
MFI; blocks 16-17 polypeptide IgM: 500 MFI; blocks 16-
17 polypeptide IgG: 2000 MFI; block 4 peptides and
blocks 16-17 polypeptide IgG subclasses: 100 MFI.
Statistical analysis
Mean MFI values were calculated for positive samples
for each peptide or polypeptide antigen. The one-way
ANOVA was used to compare IgM and IgG MFI values
between and within populations. Comparisons between
MFI values for individual peptide pairs were performed
using the post hoc Tukey-Kramer honestly significant
difference (HSD) test. Correlation of MFI values for
pairs of peptides were calculated using Pearson’sp r o -
duct-moment correlation coefficient (r). The significance
of differences between the means of two data sets was
calculated using Student’st - t e s t .AP value of less than
or equal to 0.05 was considered to be significant. All
calculations were performed using the JMP software
package (version 7.0.2, SAS Institute, Cary, NC).
Results
IgM response to parental and recombinant block 4 and
blocks 16-17 peptides
Overall, seroprevalences ranged from 10 to 42% for indi-
vidual peptides (Figure 1A), with 32% to 44% of indivi-
duals within each of the three populations having IgM
antibodies to one or more block 4 peptide (Figure 1A).
For comparison, the seroprevalence of IgM antibodies to
blocks 16-17 ranged from 35% to 65% (Figure 1A).
Within each population, the prevalence of IgM antibo-
dies to each of the four block 4 peptides was similar, i.e.,
~35% in Colombians, 10% in female adults in PNG, and
25% in Cameroonians. Additionally, when individuals
had IgM antibodies against one peptide, their sera usually
reacted with the other three peptides as well, suggesting
cross-reactive epitopes shared among the peptides.
Antibody levels for positive samples within each popu-
lation were also similar for all of the block 4 peptides
(Figure 1B). In addition, IgM levels against the four
block 4 peptides were similar among the populations.
The only exception was block 4-3 (one-way ANOVA, F
= 7.56, P = 0.0001), where block 4-3 IgM levels in
Cameroonians were higher than in Colombians (Tukey-
Kramer HSD, P ≤ 0.05).
Since the data suggest IgM block 4 antibodies were
cross-reactive, the Pearson’s correlation coefficient (r)
was calculated for IgM antibody levels for each peptide
pair (Table 1). There was a highly significant correlation
between IgM MFI values for all pair-wise block 4 pep-
tide comparisons (r = 0.3180-0.9963, P = .0065 to <
0.0001), consistent with a high level of cross-reactivity
among IgM block 4 antibodies. This correlation was
most striking in the case of the Colombian samples, for
which a nearly 1:1 relationship (r = 0.96-0.98, P <
0.0001) existed for all block 4 peptide pairs.
IgG responses to parental and recombinant block 4 and
blocks 16-17 peptides
The seroprevalences of IgG antibodies to block 4 pep-
tides (Figure 2A) were lower than the IgM prevalences
(Figure 1A) for all three populations, whereas the IgG
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16-17. These data suggest that IgG responses to block 4
epitopes are subdominant to those against blocks 16-17
in many endemic settings. In general, IgG in sera from
PNG recognized the most alleles and had the highest ser-
oprevalence compared to the other two sites. IgG
responses to block 4-2 varied among the populations
(one-way ANOVA, F = 4.16, P <0.0114), with IgG levels
in PNG being significantly higher than in Colombia
(Tukey-Kramer HSD, P ≤ 0.05). Only sera from indivi-
duals in PNG contained IgG antibodies that recognized
all four block 4 peptides (Table 2). In contrast, 90% of
sera from Colombians had IgG that was specific for only
one block 4 peptide, particularly block 4-2, with only two
samples recognizing multiple block 4 peptides (Table 2).
Both the seroprevalences and mean levels for IgG
antibodies to individual block 4 peptides showed
marked variation within each study population (Figure
Figure 1 IgM responses to MSP1 Block 4 and Blocks 16-17. (A) Seroprevalence based on n = 111 Colombian, n = 22 Papua New Guinean
and n = 72 Cameroonian samples. (B) Mean antibody levels (MFI units) for positive samples. Error bars correspond to the standard error of the
mean.
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Antigen Pair Colombia Papua New Guinea Cameroon
IgM r P r P r P
4-1 4-2 0.966 < .0001 0.9888 < .0001 0.7644 < .0001
4-1 4-3 0.9663 < .0001 0.7354 < .0001 0.3792 0.001
4-1 4-4 0.9876 < .0001 0.9963 < .0001 0.6942 < .0001
4-2 4-3 0.9877 < .0001 0.8133 < .0001 0.9263 < .0001
4-2 4-4 0.9829 < .0001 0.9859 < .0001 0.659 < .0001
4-3 4-4 0.9764 < .0001 0.7318 < .0001 0.318 0.0065
IgG r P r P r P
4-1 4-2 0.0888 0.3543 -0.1114 0.5507 0.1737 0.1699
4-1 4-3 0.2389 0.0116 0.8043 < .0001 0.6795 < .0001
4-1 4-4 0.0583 0.5432 -0.1443 0.4386 0.3889 0.0015
4-2 4-3 0.0253 0.7918 -0.036 0.8475 0.1993 0.1143
4-2 4-4 0.7882 < .0001 0.8756 < .0001 0.2502 0.0462
4-3 4-4 0.0031 0.9745 -0.105 0.5739 0.0976 0.443
*Pearson’s product moment correlation coefficient (r) and corresponding P values. Significant r values are highlighted in bold print(P < 0.05).
Figure 2 IgG responses to MSP1 Block 4 and Blocks 16-17. (A) Seroprevalence based on n = 111 Colombian, n = 22 Papua New Guinean
and n = 64 Cameroonian samples. (B) Mean antibody levels (MFI units) for positive samples. Error bars correspond to standard error of the
mean. Significantly different mean MFI values ( P ≤ 0.05) are indicated with an asterisk.
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antibodies are allele-specific. The magnitude of IgG
responses to block 4 tended to be lower than IgG
responses to blocks 16-17, and these differences were
statistically significant for all block 4 peptides for
Papua New Guinea and for block 4-2 for Colombia
(Figure 2B). Among block 4-specific antibodies, the
predominant response was to the parental alleles, with
the 68% of positive Colombian sera reacting with block
4-2 (MAD20); 20% and 15% of positive sera from PNG
reacting with peptides 4-1 (K1) and 4-2 (MAD20),
respectively. In contrast , 27% of Cameroonian sera
reacted with peptides 4-1 (K1) and 4-4 (MAD20/K1
recombinant) (Table 2). A portion of the samples,
however, contained antibodies that recognized both a
parental and one recombinant block 4 peptide, usually
blocks 4-1 + 4-3 and blocks 4-2 + 4-4 combinations
Figure 2B, Table 2). No sample recognized the combi-
nation of blocks 4-2 + 4-3 or block 4-3 + 4-4 combi-
nation. These observations, along with the correlations
observed in Table 1, suggest that in the IgG response
(1) there are major block 4 epitopes that are unique to
the two parental block 4 sequences, (2) there are epi-
topes that are shared between parent and recombinant
forms (eg. between blocks 4-1 and 4-3 and between
blocks 4-2 and 4-4, and (3) cross-reactive IgG antibo-
dies are rare between the two parental and between
the two recombinant block 4 peptides.
Comparison of overall seroprevalence of block 4 and
blocks 16-17 antibodies
In considering the seropositivity of the various study
populations, it is helpful to examine the total seropositivity
(IgM + IgG) presented in Figure 3 since the responses
were largely IgM responses in the low endemicity area
(Colombia) but had switched to IgG responses in areas of
higher endemicity (PNG and Cameroon). When IgM and
IgG results were combined to obtain the overall seropreva-
lence of antibodies to the two MSP1 regions, the seropre-
valence to individual Block 4 peptides ranged from 28 to
59% while seroprevalence to any Block 4 peptide ranged
from 52 - 73%. This contrasted to an overall seropreva-
lance of 83 to 95% for Blocks 16-17 (Figure 3).
IgG subclass distribution of block 4 and blocks 16-17
antibodies
Preliminary screening indicated that antibodies pro-
duced against both MSP1 regions were primarily of the
IgG1 and IgG3 subclasses, consequently a subset of
samples from each region was tested for these two iso-
types (Figure 4). In this isotype-specific assay, IgG1 and
IgG3 to block 4 were detected in 54% and 32% of the
samples, respectively, with both isotypes being detected
in 27% of the samples, IgG1 only in 33% , IgG3 only in
6.7%. IgG3 levels (mean MFI = 4,912), however, were
significantly higher than levels of IgG1 (mean MFI =
1035, P = 0.0009 by Student’s t test). The IgG isotype
response to block 4 appeared to form two clusters, one
cluster of samples with high IgG3 and low/no IgG1 and
a second cluster with high IgG1 and low/no IgG3 (Fig-
ure 4). In contrast, IgG1 and IgG3 to blocks 16-17 were
found in 89% and 59% of the samples, respectively, with
both isotypes detected in 75.8% of the samples, IgG1
only in 18.1%, and none of the samples containing only
IgG3. These samples appeared broadly dispersed in a
single cluster. There were no differences between the
mean MFI values for the two isotypes (IgG1 mean MFI
= 3,587; IgG3 mean MFI = 2,169; P = 0.103) in the
response to the MSP1 C-terminus. Furthermore, the
mean IgG3 response to block 4 peptides (average MFI =
2,209) was significantly higher than the mean IgG3
response to blocks 16-17 (average MFI = 1,050)
(P = 0.015, Student’s t-test).
IgG subclass data were also analysed by geographic
region (Figure 5). When the IgG1 responses to block 4
and blocks 16-17 were compared for the three regions
(Figure 5A), there was no significant pattern of variation
in relation to transmission intensity. However, a similar
comparison for the IgG3 responses revealed an increase
in IgG3 seroprevalence with increasing transmission
intensity, particularly for block 4 antibodies. Interest-
ingly in Cameroon, the area of highest transmission
intensity, the seroprevalence of block 4 IgG3 antibodies
Table 2 Specificity of IgG antibodies for block 4 allelic
forms in each study population and in all study
populations
a
Block 4
Peptide(s)
Colombia Papua New
Guinea
Cameroon Total
1 9% 20% 9% 13%
2 6 81 52 74 0
39006
4 4.5 0 27 7
1+2 4.5 5 0 4
1 + 3 0502
1 + 4 0594
2 + 3 0000
2+4 4.5 10 9 7
3 + 4 0000
1+2+3 0 10 9 6
1+2+4 0 10 9 6
1+3+4 0000
2+3+4 0502
1+2+3+4 0 15 0 6
aPercent positive based on IgG samples reacting with one or more block 4
peptides: 22/111 samples from Colombia, 19/22 from PNG, and 11/61 from
Cameroon. Total: Percent positive based on a total of 52 responders from all
groups
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(64%) in samples tested for IgG subclass.
IgM response to parental and recombinant block 4 and
blocks 16-17 peptides in cord blood
Nine cord blood samples were available from Papua
New Guinea for evaluation of the response of the fetus
to MSP1 antigens in utero. Two of these samples con-
tained IgM antibodies that exceed adult background
cutoff levels for one or more block 4 peptides and
blocks 16-17 (P15 and P42) (Figure 6). However, five of
t h en i n ec o r db l o o ds e r a( P 5 9 ,P 1 5 ,P 1 1 ,P 6 2 ,P 4 2 )h a d
measureable MSP1-specific IgM antibodies as compared
to four sera (P28, P58, P72, P117) with undetectable
levels of these antibodies, suggesting that fetal responses
to both block 4 and blocks 16-17 are common following
in utero exposure to P. falciparum.
Discussion and Conclusions
Block 4 is one of the most clearly defined sites of intra-
genic recombination within the MSP1 sequence [4,10].
While extensive studies have analysed the immune
responses to the MSP1 block 2 repeat region and blocks
16-17, few immunological studies have been performed
on MSP1 block 4. Immune recognition of this region
was first shown using a mouse monoclonal antibody
that bound an isolate-specific epitope within block 4
[1,11]. Later, human antibodies were detected to one
allelic form of block 4 in sera of German adults follow-
ing P. falciparum infection and in Burkina Fasoan
infants and adults [12]. The seroprevalence of anti-block
4 IgG antibodies was lower in German adults under-
going a primary (14%) or subsequent (21%) responses
compared to Burkina Fasoan infants (50%) following
initial malaria infections. Subsequently, allele-specific
Figure 3 Overall seroprevalence of IgM or IgG antibodies to MSP1 Block 4 and Blocks 16-17. Seroprevalence based on n = 111
Colombian, n = 22 Papua New Guinea and n = 64 Cameroonian samples.
Figure 4 IgG subclass distribution of MSP1 Block 4 and Block 16-17. Sera from samples that contained antibodies to one or more Block 4
peptides (left panel) or Blocks 16-17 (right panel) were assayed for IgG1 and IgG3 isotypes. Colombia (n = 21), Papua New Guinea (n = 9), and
Cameroon (n = 11). Clustering of isotype distribution is indicated by ellipses.
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malaria-exposed individuals in a study utilizing a panel
of MSP1 recombinant polypeptides that included pep-
tides spanning block 4 of the K1, MAD20 and RO33
parasites isolates [13]. IgG reactive with MAD20, K1
a n dR O 3 3b l o c k4w e r ed e t e c t e di nc h i l d r e n( 1 - 5y ) ,
adolescents (6-14 y), and adults (>14 y). The seropreva-
lence of antibodies was similar for all three block 4
sequences in adults, while the responses were more
variable among children and adolescents. However, little
was known about the specificity and cross-reactivity of
IgM and IgG block 4 antibodies prior to the current
study.
In this study, immune recognition of dimorphic and
r e c o m b i n a n tM S P 1b l o c k4p e p t i d e sb yI g Ma n dI g G
antibodies from malaria-exposed subjects from Colom-
bia, Papua New Guinea and Cameroon was evaluated.
For comparison, antibody responses to the MSP1 C-
Figure 5 IgG subclass responses to MSP1 Block 4 and Blocks 16-17. (A) IgG1 and (B) IgG3 seroprevalences based on n = 21 Colombian, n =
9 Papua New Guinean and n = 11 Cameroonian samples.
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immunogenic in malaria-infected individuals [14] were
examined. Despite the diverse characteristics of the
study populations, a consistent pattern emerged with
respect to IgM and IgG antibody recognition of block 4
and blocks 16-17. Sera from all three populations con-
tained IgM and IgG antibodies to the block 4 synthetic
peptides and to blocks 16-17. For IgM, MSP1 block 4
and blocks 16-17 seroprevalences in most instances
were similar ranging from 44% and 66% in Colombia,
32% and 35% in Papua New Guinea, and 40% and 43%
in Cameroon, respectively. In contrast, IgG seropreva-
lences were much lower for MSP1 block 4 than for
blocks 16-17 in the three populations. When IgM and
IgG recognition are combined, more than half of the
individuals from each population produced antibodies
recognizing MSP1 block 4, while more than 80% pro-
duced antibodies to MSP1 block 16-17.
The similarity in prevalence and magnitude of the IgM
response to MSP1 block 4 and blocks 16-17 suggests
that these regions are equi-dominant during the initial
immune response in contrast to dominance of a later
MSP1 IgG response specific for the blocks 16-17. Thus,
it appears that exposure to P. falciparum MSP1 through
natural infection in all endemic settings generally
resulted in the preferential expansion of IgG-producing
B cells specific for blocks 16-17 over those specific for
MSP1 block 4. Studies on humans naturally exposed to
malaria infection have reported high seroprevalence
levels of antibodies against MSP1 C-terminal epitopes
[12,14-16].
The IgM response, which reflects the repertoire of
early B cells that have not undergone isotype-switching,
was highly cross-reactive among the parental and
recombinant block 4 sequences as demonstrated by
pair-wise comparisons (Table 1). This high level of
cross-reactivity is remarkable since only ~28% sequence
homology exists among block 4 parental and recombi-
nant sequences. IgM antibodies may be directed against
amino acid residues shared by all four block 4 sequences
or, alternatively, may display low affinity binding of
similar conformational determinants preserved among
the alleles by conservative amino acid substitutions. It is
notable that cross-reactive block 4 IgM antibodies were
also detected in cord blood samples from Papua New
Guinea indicating that these antibodies may be pro-
duced by the foetus during the response to malaria anti-
gens in utero.
The IgG block 4 response was specific and clearly dis-
criminated among MSP1 block 4 sequences. A majority
of individuals produced IgG antibodies specific for one
of the two parental block 4 peptides (i.e., K1 or
MAD20) and these antibodies may contribute to isolate-
specific immunity to P. falciparum. A subgroup of sam-
ples had IgG antibodies that cross-reacted with epitopes
shared by one parental and one recombinant allele.
Pair-wise comparisons of IgG levels to MSP1 block 4
peptides (Table 1), as well as the specificity of individual
samples (Table 2) mapped these two allelic epitopes to
dimorphic sequences localized within a 19 amino acid
region upstream of the putative block 4 recombination
site (Figure 7). However, in all three study populations,
Figure 6 Cord Blood IgM responses to MSP1 Block 4 and Blocks 16-17. Mean antibody levels (MFI units) for cord blood samples from
Papua New Guinea. Asterisks indicate samples that were above adult cut-off values for the individual peptides.
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(Block 4-1) and MAD20 (block 4-2) sequences were
more prevalent than antibodies recognizing the recom-
binant (block 4-3 and 4-4) forms.
The Colombian samples examined in this study were
obtained from subjects residing in relatively close proxi-
mity to the site where P. falciparum MSP1 genotyping
had been performed [5]. Parasites expressing all four
MSP1 block 4 sequences were found in this low-trans-
mission region. In the current study, Colombian sera
exhibited the highest block 4 IgM seroprevalence (Fig-
ure 1A), the highest cross-reactivity of IgM for the four
peptide pairs (Table 1), but the most restricted IgG spe-
cificity for single block 4 peptides compared to the
other two higher-transmission regions. In Papua New
Guinea and Cameroon, where higher malaria transmis-
sion occurs, a much broader range of specificities devel-
oped, including a higher proportion of sera containing
IgG that recognized two or more block 4 allelic
sequences.
IgG subclass analysis revealed that MSP1 block 4 and
blocks 16-17 epitopes also differ in isotype switching
preference. In general, the majority of samples contained
both IgG1 and IgG3 antibodies to blocks 16-17,
whereas, the response to block 4 was more polarized,
with one cluster of samples containing either high levels
of IgG3 with or without lower levels of IgG1 and a sec-
ond cluster of samples containing predominantly IgG1.
While block 4 induced both IgG1 and IgG3 antibodies,
a greater proportion of these antibodies are biased
toward a high IgG3 response than observed for blocks
16-17. When IgG subclass data were analysed by geo-
graphic region, it appeared that production of IgG3 anti-
bodies, particularly against block 4, was dependent on
malaria transmission intensity. A relatively high IgG1
and low IgG3 seroprevalence was seen against block 4
in the area of lowest malaria transmission while the pre-
valence of IgG3 antibodies was higher in the intermedi-
a t et r a n s m i s s i o nr e g i o na n dm a x i m a li nt h ea r e ao f
highest transmission, exceeding the IgG1 seroprevalence.
T h ep o t e n t i a lr e l e v a n c eo ft he MSP1 block 4-specific
antibody response to protective immunity remains to be
explored. Antibodies against the MSP1 83 kDa proces-
sing fragment containing block 4 can inhibit the growth
of P. falciparum [17], as well as block the activity of
inhibitory antibodies to the MSP1 C-terminus [18].
MSP1 block 2 antibodies, which are predominantly IgG3
[19], are highly efficient in mediating the monocyte-
dependent antibody-mediated cellular inhibition (ADCI)
of P. falciparum [20]. It has been suggested that variant
MSP1 epitopes, such as the block 2 repeat region, are
more likely to stimulate B cells that class switch to IgG3
production, and that these antibodies may be more
effective in mediating ADCI [19,20]. Since many serum
samples recognizing MSP1 block 4 peptides contained
high levels of IgG3 in the current study, these block 4
antibodies may exert biological activity against blood
stage parasites through monocyte-mediated inhibition of
parasite growth.
The observation that individuals in the low transmis-
sion region produce antibodies against only a single
block 4 peptide while those from intermediate and high
malaria transmission regions produce antibodies against
multiple block 4 peptides suggests that antibodies
against the complete array of block 4 sequences may be
associated with increased immunity to malaria. Differ-
ences in seropositivity among small numbers of indivi-
duals primed by natural infection may allow parasites
expressing certain block 4 alleles to survive in indivi-
duals lacking antibodies against those particular alleles.
Thus, balancing selection, ie. frequency dependent
immune selection of block 4 peptide alleles within the
parasite population, would exist at all transmission
intensities but may be more forceful in areas of higher
malaria transmission. Given this scenario, a polyvalent
block 4 vaccine should induce immunity to all four
alleles, even in individuals naturally primed against only
one or a few block 4 alleles.
Subdominant epitopes play an important role in
immunity to viral pathogens [21-24] and it has been
Figure 7 Mapping of dimorphic allelic IgG MSP1 Block 4 epitopes. Human antibodies that reacted with Block 4-1 and 4-3 (black) and with
Block 4-2 and 4-4 (blue) recognized allelic sequences indicated by asterisks within the boxed region.
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in immunity to Plasmodium [25]. This possibility is par-
ticularly pertinent in view of the lack of protective effi-
cacy of a highly-immunogenic MSP1 42 kDa C-terminal
vaccine in children in a recent Phase IIb trial [26]. To
date, the only blood-stage malaria vaccine that has been
documented to provide partial protection in a Phase I-
2b trial, is the Combination B vaccine containing MSP1
blocks 3 and 4 fused to a universal circumsporozoite
protein T cell epitope along with merozoite surface pro-
tein-2 and the ring-infected erythrocyte surface antigen
[27]. Genetic analyses indicating that MSP1 block 4 may
be a locus of balancing selection along with the results
of the current study demonstrating IgG discrimination
among block 4 allelic peptides and increased production
of anti-block 4 antibodies of certain IgG subclasses in
areas of high malaria transmission suggest that the
immune response to MSP1 block 4 epitopes is biologi-
cally and evolutionarily relevant and may contribute to
the protective antibody response to P. falciparum.
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